These findings suggest that suppression of TBK1 and IKKε by using amlexanox can attenuate cholestasis‐induced chronic liver injury and its associated fibro‐inflammatory responses in mice through modulating NF‐κB activation. Here, IKBKE is linked to cholestasis.